治疗遗传性血管性水肿新药艾替班特概述  

Overview of Icatibant,a New Drug against Hereditary Angioedema

作　　者：饶志方 

机构地区：[1]华润武钢总医院,武汉430080

出　　处：《中国药师》2014年第6期1033-1034,1061,共3页China Pharmacist

摘　　要：艾替班特和缓激肽结构类似,与其竞争性地结合缓激肽B2受体,具有良好的药动学特性,对急性发作期遗传性血管性水肿(HAE)的患者疗效佳。同时在发病的第一时间内,患者可以安全地自我治疗。目前的文献报道提示,艾替班特治疗获得性血管性水肿(AAE)的效果与治疗HAE一样安全、有效,或许将来艾替班特也可用于AAE的治疗。Objective：To get knowledge of the latest development of icatibant,a drug against hereditary angioedema （HAE）.Methods：Many literatures on icatibant were selected from home and abroad.Results ＆ Conclusion：Icatibant is structurally similar to bradykinin and acts as a potent,selective and competitive antagonist of bradykinin type 2 receptor,it also has good pharmacokinetic profile,therefore,it is a good drug against acute episodes of HAE.At the same time,patients can cure HAE by self-administrating icatibant during an acute attack.From the epidemic factor and treatment instances,Icatibant is a safe and effective drug against acquired angioedema（AAE）.Therefore,it will be approved for the treatment of AAE in the future.

关 键 词：艾替班特 缓激肽B2受体 遗传性血管性水肿 获得性血管性水肿 

分 类 号：R97[医药卫生—药品]